Michael Bogenschutz: At our large, outpa tient substance abuse program at the Uni versity of New Mexico, we generally try to treat drug abusers pharmacologically to help them through detoxification. We used aman tadine for a number of years and have also used a number of other medications-includ ing baclofen, disulfiram, and propranololbased on what has seemed most promis ing at the time. With each of these medications, some patients will say that it made a big dif ference. I believe they help, but I wonder how much. The empirical findings for all of them are still equivocal-some promis ing results on the one hand, but without substantiation in large clinical trials. On the other hand, I am sure that the structure and support we supply along with medications contribute significantly to our patients' recov eries.
John Roll: Do you think those medications you use affect addiction directly or do they affect co-occurring psychiatric condi tions that may be enabling or facilitating the drug use?
Bogenschutz: I think they affect addition directly. These patients are in our primary addiction treatment program, and they may or may not have co-occurring disorders. We target early withdrawal symptoms, like crav ing, and hope to normalize the function of a person's brain. Disulfiram or gamma aminobutyric acid (GABA)-ergic medica tions can also affect the reinforcement value or effects of cocaine or methamphetamine.
Roll:
One point that I think bears high lighting is that medications compensate for some of the reinforcing effects of drugs, but only some. At one level, drugs reinforce abuse because of their pharmacology, and it makes perfect sense to target those aspects of reinforcement with pharmaceutical inter ventions. However, drugs also accrue rein forcing efficacy by other means, like the asso ciations of a drug-using peer group. I've heard anecdotal evidence that some women initiate use of methamphetamine to take advantage of its anorectic properties and control weight. Sex workers have told me that they could never do their job without drugs, so they have an economic incentive to continue using them. Medications don't directly modify these sorts of reinforcement and therefore may not constitute treatment all by themselves.
Bogenschutz:
A good example of that point is the experience with naltrexone. When naltrexone was first released, many thought it would be 100 percent effective for opiate dependence, because it functions like an antidote for heroin. However, in the real world, naltrexone has had only a small impact on opioid dependence treatment. Most patients simply won't take it; it causes dys phoria in opiate abusers, and it doesn't decrease craving. Patients who do take it can simply stop if they want to resume heroin use. We would likely face similar problems with some of the medications Dr. Kampman dis cusses, particularly the cocaine vaccine.
DeMarzo: I have heard Nora Volkow, NIDA's director, make the case that developing effec tive medications to treat stimulant addic tion is an avenue to reducing the stigma of addiction and legitimizing addiction treat ment services. That makes sense to me, and it's one of the reasons I find this research exciting. Bogenschutz: Safety is another primary con cern in deciding whether to implement a medication intervention in a program or use it with a particular patient. Especially when using a medication off-label, that is, for a purpose other than the FDA-approved ones, the burden is on prescribers to show they have adequately considered the poten tial safety issues and have done everything to minimize the risks. Some of the medica tions Dr. Kampman discusses don't require anything more than monitoring liver enzymes, reviewing patient history, and/or perform ing a physical exam to rule out cardiac dis ease or similar conditions. Others can pose significant risk. Disulfiram is perhaps the most promising medication mentioned in the article; however, it's also probably the most dangerous, because the alcohol-disul firam interaction can be fatal, and because very rarely, there have been cases of patients developing liver failure so severe that they needed liver transplants. Gamma-vinyl GABA raises concerns about visual field defects. Modafinil and the anticonvulsants are probably pretty safe, but even they have sedative effects, neurological side effects, and potential hepatotoxicity and other organ effects.
Grounds for implementation
Roll: I'd add that you need to have a dis cussion with the patient to inform him or her that you're recommending an off-label use of the medication and to enumerate potential risks. Otherwise, most patients will assume that your prescription is an evi dence-based practice, though the evidence is not necessarily there.
Bogenschutz:
Absolutely. In sum, from my perspective, clinical judgment has to be the primary basis for implementing or not imple menting use of these medications at this time. The evidence isn't strong enough for a program to make a guideline that patients should receive any of them. If a program does decide to use one, however, it will need to create guidelines for using it safely. With disulfiram, for example, the guideline would require clinicians to make sure that people are clearly informed that the medication is being used off-label, that screening for adverse effects is appropriate, and that people get the information they need regarding the risks of using alcohol or cocaine while on the medication.
DeMarzo:
Cost is a big issue for us. If an intervention is too expensive, we simply won't use it. If we, as a community-based agency with limited resources and experi ence with medical interventions, decide to implement a medical intervention, we have to consider infrastructure, training, licens ing regulations, and staffing issues. One of the greatest challenges with the transfer of research to practice is that researchers have limited resources that often do not afford the opportunity to build front-end, costbenefit analysis into the studies.
Roll: As a researcher, I think there is so much that is exciting to be learned about phar maceutical approaches to stimulant abuse that I would hate to see us become overly concerned with cost at this stage. Once we get a better feel for which approaches really work, how, and for whom, cost will become a much more salient issue.
Bogenschutz:
Although cost-benefit is important on a systems and program level, cost generally drops out of the equation at the clinical level. The formulary or the insur ance company tells you what the patient can and can't have. The clinician's primary role with regard to these medications is to weigh the benefits and potential adverse effects. The overall clinical challenge is to get the most out of the mix of marginally or modestly effective treatments that we have available for stimulant abuse. Treatment providers will have to figure out optimal dosage and duration for pharmacological treatment, and what kinds of psychosocial components should be used with the par ticular medication or vaccine.
The decision to use a medication or par ticular behavioral intervention will proba bly also depend on individual patient char acteristics, such as addiction severity, gender, other substances abused, psychiatric comor bidity, and so on. Sometimes these subgroups can be identified in the analyses of larger tri als, which may prompt subsequent trials of those subgroups, as was done with propra nolol. There's an interesting secondary analy sis of the COMBINE study data for nal trexone showing that efficacy in that trial was limited to people who had a particu lar mu opioid receptor polymorphism (Anton et al., 2008) . Such information may allow us to match treatment plans to particular subgroups or individuals and thus magnify the effects of what are now marginally effec tive treatments.
Roll: I think we are just starting to figure out how to incorporate pharmaceuticals into treatment for stimulant abuse, and Dr. Kamp man has made a good start. He suggests a strategy of matching medications to the phase of treatment, such as initiation and maintenance, and I think one might do the
